Products for Research Use Only

Tirofiban-d9

CAT: 0804-HY-17369BS-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17369BS-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tirofiban-d9 is deuterium labeled Tirofiban.
CAS Number
1332075-40-7
Product Name Alternative
L700462-d9; MK383-d9
UNSPSC
12352005
Target
Integrin; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Cytoskeleton; Others
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Solubility
10 mM in DMSO
Smiles
O=S(N[C@H](C(O)=O)CC1=CC=C(C=C1)OCCCCC2CCNCC2)(C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O
Molecular Formula
C22H27D9N2O5S
Molecular Weight
449.65
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Diaz JF, Cardenal R, Gomez-Manchero A, Sanchez-Gonzalez C. Safety and efficacy of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab. Cardiovasc Hematol Agents Med Chem. 2011 Jul 1;9 (3) :147-53.|[3]Valgimigli M, Biondi-Zoccai G, Tebaldi M et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. Eur Heart J. 2010 Jan;31 (1) :35-49.|[4]Valgimigli M, Tebaldi M. Safety evaluation of tirofiban. Expert Opin Drug Saf. 2010 Sep;9 (5) :801-19.|[5]van 't Hof AW, Valgimigli M. Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban. Drugs. 2009;69 (1) :85-100.|[6]Winter JP, Juergens CP. The role of tirofiban in the management of coronary artery disease. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8 (2) :138-46.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products